Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-labeled scFv-8
- Development stage
- Preclinical
- Lead developer
- Mayo Clinic
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-labeled scFv-8 is a Gallium-68 (68Ga) radiolabeled single-chain variable fragment (scFv) antibody targeting hypoglycosylated mucin-1 (MUC1) [4345]. Developed by researchers at the Mayo Clinic, this radiodiagnostic agent is designed for the molecular imaging and detection of cholangiocarcinoma (CCA) [4345]. Hypoglycosylated MUC1 is highly expressed on CCA cells, exposing tumor-specific epitopes that can be selectively targeted [4345]. The scFv-8 fragment was isolated using ribosome display technology and radiochemically conjugated with Gallium-68 for positron emission tomography (PET) imaging [4345]. In preclinical orthotopic xenograft mouse models of CCA, 68Ga-labeled scFv-8 demonstrated selective binding, favorable biodistribution, and localization within orthotopic tumors, showing potential as a precision-targeted theranostic agent [4345].
- Other names
- 68Ga-scFv-8Gallium-68 scFv-8Gallium68 scFv-8Gallium 68 scFv-8Gallium-68-labeled scFv-8Gallium68-labeled scFv-8Gallium 68-labeled scFv-8
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on 68Ga-labeled scFv-8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-labeled scFv-8.